We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Calithera Biosciences Inc (CALA) USD0.0001

Sell:$0.71 Buy:$0.72 Change: $0.0818 (10.25%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.0818 (10.25%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.0818 (10.25%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The Company is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. It has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. It has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The Company is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC).

Contact details

343 Oyster Point Blvd # 200
United States
+1 (650) 8701000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$57.32 million
Shares in issue:
74.93 million
United States
US dollar

Key personnel

  • Susan Molineaux
    President, Chief Executive Officer, Co-Founder, Director
  • Stephanie Wong
    Chief Financial Officer, Company Secretary
  • Sumita Ray
    Senior Vice President, Chief Compliance Officer, General Counsel
  • Christopher Molineaux
    Senior Vice President - Development
  • Francesco Parlati
    Senior Vice President - Research
  • Eric Sjogren
    Senior Vice President - Drug Discovery
  • Emil Kuriakose
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.